Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWP715
- Development stage
- Preclinical
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
01
Overview
DWP715 is an investigational small molecule drug candidate being developed by Daewoong Pharmaceutical for the treatment of pancreatitis. Currently in the preclinical stage of development, the drug is part of Daewoong's synthetic new drug (NCE) pipeline. While specific biological targets and the precise mechanism of action have not been publicly disclosed by the company, DWP715 is designed to address the inflammatory and tissue-damaging processes associated with pancreatic inflammation. It represents a component of Daewoong's broader research and development efforts in gastrointestinal and inflammatory diseases.
Beyond the preview
Go deeper on DWP715.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWP715.